Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

NCT01285518 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: PF-05231023
DRUG: PF-05231023
DRUG: PF-05231023
DRUG: PF-05231023
DRUG: PF-05231023
DRUG: PF-05231023
DRUG: PF-05231023
OTHER: Placebo

Sponsor

Pfizer